Oncolytics Biotech Inc T.ONC

ASCO 2024 - Trial in Progress abstracts

[Noteable]

Trials in Progress posters provide an opportunity for members of the research community to present ongoing trials, foster collaboration, and discuss correlatives and novel trial designs. In addition, Trials in Progress highlight the transition of emerging biologic pathways and new agents into the clinic—providing "coming attractions" for oncologists in clinical practice.

https://conferences.asco.org/am/trials-progress-abstract-submission-guidelines

[Noteable]

Criteria Guidelines:  -- Enrollment must have already begun or have been completed with no data analysis available by the submission deadline (there are no exceptions to this criterion). It is acceptable if the trial has not enrolled its first patient yet. --  Clinical trial registry number (required)

[Noteable]

Trials in Progress posters provide an opportunity for members of the research community to present ongoing trials, foster collaboration, and discuss correlatives and novel trial designs. In addition, Trials in Progress highlight the transition of emerging biologic pathways and new agents into the clinic—providing "coming attractions" for oncologists in clinical practice. https

[itntdf]

https://meetings.asco.org/abstracts-presentations/235322

[Noteable]

Good find on ONCY's biomarker presentation at ASCO 2024. -  at a time in preparation for ONCY's acquisition and pelareorep's subsequent accelerated approval Pelareorep driven blood TIL expansion in patients with pancreatic, breast, and colon cancer Authors: Richard Trauger, Houra Loghmani, Amy Kupic, Thomas Heineman